Literature DB >> 34078309

Prophylactic gastrostomy in locally advanced head and neck cancer: results of a national survey among radiation oncologists.

Tatiana Dragan1, Fréderic Duprez2, André Van Gossum3, Akos Gulyban4, Sylvie Beauvois5, Antoine Digonnet6, Yassine Lalami7, Dirk Van Gestel5.   

Abstract

BACKGROUND: Nutritional complications in patients with locally advanced head and neck cancer (LA-HNC) treated by concurrent chemoradiotherapy (CCRT) often lead to placement of a prophylactic gastrostomy (PG) tube, while indication lacks harmonization. Our aim was to explore the current PG tube utilization among Belgian radiation oncology centers.
METHODS: A survey was distributed to all 24 Belgian Radiation oncology departments, with questions about the number of patient treated per year, whether the PG indication is discussed at the multidisciplinary board, placement technique, time of starting nutrition and removal, its impact on swallowing function and importance of clinical factors. For the latter Relative Importance and Discordance Indexes were calculated to describe the ranking and agreement.
RESULTS: All 24 centers submitted the questionnaire. Twenty three treat more than 20 head and neck (HNC) patients per year, while four (1 in 21-50; 3 in 51-100) are not discussing the gastrostomy tube indication at the multidisciplinary board. For the latter, endoscopic placement (68%) is the dominant technique, followed by the radiologic (16%) and laparoscopic (16%) methods. Seventy-five percent start the enteral nutrition when clinically indicated, 17% immediately and 8% from the start of radiotherapy. Majority of specialists (19/24) keep the gastrostomy tube until the patient assume an adequate oral feeding. Fifteen centres are considering PG decrease swallowing function. Regarding factors and their importance in the decision for the PG, foreseen irradiated volume reached highest importance, followed by 'anatomical site', 'patients' choice' and 'postoperative versus definitive' and 'local expertise', with decreasing importance respectively. Disagreement indexes showed moderate variation.
CONCLUSIONS: The use of a PG tube for LAHNC patients treated by CCRT shows disparity at national level. Prospective studies are needed to ensure proper indication of this supportive measure.

Entities:  

Keywords:  Endoscopic gastrostomy; Head and neck cancer; Radiotherapy; Survey

Year:  2021        PMID: 34078309     DOI: 10.1186/s12885-021-08348-9

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  20 in total

1.  Interruptions of Head and Neck Radiotherapy Across Insured and Indigent Patient Populations.

Authors:  Kimberly Thomas; Travis Martin; Ang Gao; Chul Ahn; Holly Wilhelm; David L Schwartz
Journal:  J Oncol Pract       Date:  2017-03-07       Impact factor: 3.840

2.  Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it.

Authors:  Katherine A Hutcheson; Mihir K Bhayani; Beth M Beadle; Kathryn A Gold; Eileen H Shinn; Stephen Y Lai; Jan Lewin
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-11       Impact factor: 6.223

3.  Association of Treatment at High-Volume Facilities With Survival in Patients Receiving Chemoradiotherapy for Nasopharyngeal Cancer.

Authors:  Vivek Verma; Pamela K Allen; Charles B Simone; Hiram A Gay; Steven H Lin
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-01-01       Impact factor: 6.223

4.  Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome.

Authors:  Sarah Deschuymer; Daan Nevens; Frederic Duprez; Jean-François Daisne; Rüveyda Dok; Annouschka Laenen; Mia Voordeckers; Wilfried De Neve; Sandra Nuyts
Journal:  Radiother Oncol       Date:  2020-02-07       Impact factor: 6.280

5.  Predictive modelling for swallowing dysfunction after primary (chemo)radiation: results of a prospective observational study.

Authors:  Miranda E M C Christianen; Cornelis Schilstra; Ivo Beetz; Christina T Muijs; Olga Chouvalova; Fred R Burlage; Patricia Doornaert; Phil W Koken; C René Leemans; Rico N P M Rinkel; Marieke J de Bruijn; G H de Bock; Jan L N Roodenburg; Bernard F A M van der Laan; Ben J Slotman; Irma M Verdonck-de Leeuw; Hendrik P Bijl; Johannes A Langendijk
Journal:  Radiother Oncol       Date:  2011-09-08       Impact factor: 6.280

6.  Weight loss as a prognostic factor for recurrence and survival in oropharyngeal squamous cell carcinoma patients.

Authors:  Antuani Rafael Baptistella; Klisman Drescher Hilleshein; Caroline Beal; Juliana S Brambatti; Ruggero Caron; Shaline Ferla Baptistella; Radamés Ádamo Zuquello; Carina Rossoni; Gabriel Manfro
Journal:  Mol Clin Oncol       Date:  2018-10-05

7.  Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.

Authors:  Johannes A Langendijk; Patricia Doornaert; Irma M Verdonck-de Leeuw; Charles R Leemans; Neil K Aaronson; Ben J Slotman
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

8.  Patient choice for high-volume center radiation impacts head and neck cancer outcome.

Authors:  Arash O Naghavi; Michelle I Echevarria; Tobin J Strom; Yazan A Abuodeh; Puja S Venkat; Kamran A Ahmed; Stephanie Demetriou; Jessica M Frakes; Youngchul Kim; Julie A Kish; Jeffery S Russell; Kristen J Otto; Christine H Chung; Louis B Harrison; Andy Trotti; Jimmy J Caudell
Journal:  Cancer Med       Date:  2018-09-02       Impact factor: 4.452

9.  Dose to swallowing structures and dysphagia in head and neck Intensity Modulated Radiation Therapy - A long term prospective analysis.

Authors:  Ram Abhinav Kannan; T R Arul Ponni
Journal:  Rep Pract Oncol Radiother       Date:  2019-11-01

10.  Critical weight loss is a major prognostic indicator for disease-specific survival in patients with head and neck cancer receiving radiotherapy.

Authors:  J A E Langius; S Bakker; D H F Rietveld; H M Kruizenga; J A Langendijk; P J M Weijs; C R Leemans
Journal:  Br J Cancer       Date:  2013-08-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.